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Quadriceps dysfunction is an important comorbidity in chronic obstructive pulmonary disease (COPD), [1] [2] [3] which is the third leading cause of mortality worldwide. 4 Up to 30% of people with COPD exhibit quadriceps weakness, 2 and this is known to relate to increased healthcare usage and mortality. 5, 6 Skeletal muscle consists of 2 fiber types, the "fast" glycolytic type II fibers and "slow" oxidative type I fibers. In the quadriceps of healthy humans, these fibers are present in approximately equal proportions, but a consistent feature of quadriceps dysfunction in COPD is a fiber shift to an increased number of type II fibers, 7 which itself is associated with reduced exercise capacity 8, 9 and a poor prognosis independent of disease severity judged spirometrically. 10 For these reasons, elucidating the molecular mechanisms (e.g., impaired protein synthesis, protein degradation, oxidative stress, inflammation) involved in quadriceps dysfunction, as well as mechanisms of fiber shift, are a current research priority.
There is a lack of consensus regarding the underlying molecular mechanisms for quadriceps dysfunction in COPD. For example, muscle-RINGfinger-protein-1 (MURF-1) and Atrogin-1 E3 ligases are known to be involved in catabolic pathways in murine models, 11 yet human studies in stable COPD have had conflicting results. Specifically, increased quadriceps expression of Atrogin-1, but not MURF-1, in COPD subjects was reported by Plant et al. 12 and Lemire et al. 13 Conversely, Doucet et al. found both increased Atrogin-1 and MURF-1 in the quadriceps of COPD patients, 14, 15 whereas Natanek et al. found no difference in MURF-1 expression between patients and controls and lower Atrogin-1 levels in COPD subjects. 16 Similarly Lemire et al. discovered increased activation of the p38 MAPK inflammatory pathway, 13 but Riddoch-Contreras et al. found no difference between COPD and control subjects. 17 These conflicting findings make the progression to development of medicines that address these pathways more difficult because of uncertainty as to whether they represent a valid target. 18 We speculated that molecular signaling might differ between type I and type II fibers and that this could be a reason behind discordant findings in different cohorts. Specifically, because molecular analysis in COPD has hitherto relied exclusively on whole muscle samples, it is possible that biologically relevant findings might be overlooked if they are present only in a single fiber type. Laser capture microdissection (LCM) has been used to isolate myofibers previously, 19, 20 although only in very small numbers and not in patients with COPD. Thus the aim of this study was to develop a method for LCM that could be used on optimum cutting temperature (OCT) compound embedded specimens already held by research groups in this area and to test whether this method allows for observation of fiber-specific differences in expression of genes involved in protein synthesis or degradation pathways. Some of the results of these studies have been previously reported in abstract form. 21 
MATERIALS AND METHODS
Subjects. Biopsies from 12 men with a clinical diagnosis of COPD and 6 healthy age-matched men were analyzed. Study approval was granted by the National Research Ethics Service Committee London -Harrow (study reference 11/LO/1636; ClinicalTrials.gov number NCT01471587) and carried out under the principles of the Declaration of Helsinki. Written, informed consent was obtained from all participants.
Subjects had to be between ages 40 and 90 years inclusive; a clinical diagnosis of COPD was confirmed by >10 pack-year smoking history and post-bronchodilator spirometry demonstrating a forced expiratory volume in 1 second (FEV 1 ) of < 80% predicted and FEV 1 /forced vital capacity (FVC) of < 0.7. Exclusion criteria were pregnancy, inability to provide written informed consent, exercise-limiting neuromuscular disorders, respiratory disorders other than COPD, and active participation in a clinical trial of an investigational medicinal product. Healthy, age-matched control subjects were additionally recruited. Biopsies from nonsmoker controls were selected to study differences between COPD and healthy subjects. All subjects were clinically stable without exacerbations for at least 4 weeks before study measurements.
Study Assessments. Subjects underwent comprehensive phenotypic assessment, and the data from COPD patients were also used for the ERICA (evaluating the role of inflammation in chronic airways disease) study, for which study assessments have been described previously. 22 Study assessments were carried out over 2 visits. We measured height and weight, and fat free mass was estimated using single-frequency (50 kHZ) bioelectrical impedance analysis by means of TANITA BC 418MA (Tanita Corporation, Tokyo, Japan) and a disease-specific regression equation. 23 Postbronchodilator spirometry (CompactLab system; Jaeger, Wurzburg, Germany) was determined in accordance with European Respiratory Society guidelines. 24 Six-minute walk distance was measured in accordance with the guidelines of the American Thoracic Society. 25 Quadriceps maximal volitional contraction (QMVC) force was measured using the technique of Edwards et al. 26 Patients were verbally encouraged to make a maximal contraction by pushing against an inextensible strap placed above the ankle. The maneuver was repeated 6 times with a minimum 20-s interval between efforts. We used the highest contraction value which could be sustained for 1-s for analysis. Greater detail on these study assessments has been described previously. 22 All subjects had percutaneous biopsy of the vastus lateralis muscle from the leg used for quadriceps strength measurements under local anesthetic using the Bergstorm method. 27 Biopsies were carried out on a day without strenuous physical activity, after 20 min of rest on the second visit following at least 4 h of fasting. Biopsy specimens were mounted on cork, embedded in OCT compound (Tissuetek compound) and frozen in precooled isopentane before being placed in liquid nitrogen. Biopsy aliquots were also placed directly in cryovials and frozen in liquid nitrogen. All samples were stored at -80 8C until analysis.
Muscle Biopsy Analyses.
Sectioning. Serial OCTembedded muscle sections (10 lm) with fibers predominantly in transverse section were cut at -20 8C in sterile conditions using nitrile gloves to minimize RNAse contamination. Sections were mounted on standard 1-mm glass slides and stored at -80 8C until analysis.
Immunostaining. For LCM, slides with 10 lm muscle cryosections were immediately fixed with 4% paraformaldehyde (10 min), and washed 3 times (3 min) with 1% phosphate buffered saline and 0.05% Tween 20 (PBST). To determine type II fibers, samples were incubated with MY32 (mouse immunoglobulin [Ig] G1 anti-fast myosin) (Life Technologies, Carlsbad, California) diluted 1:200 in PBST in a humidified chamber overnight at 4 8C. After being washed thrice with PBST (3 min), they were incubated for 1 h at room temperature in the dark with a secondary antibody, A21121 (AlexaFluor 488 goat anti-mouse IgG1) diluted 1:200 in PBST. The slides were then washed thrice with PBST for 3 min before being air-dried for 1 h in the dark.
For fiber typing, sections were air-dried for 30 min at room temperature, and the slides were incubated at room temperature (20 min) with 5% milk in PBST. The slides were then washed with PBST 3 times for 5 min each before being incubated for 1 h at room temperature with a mix of primary antibodies diluted in PBST; A4.840 (mouse . The slides were again washed thrice with PBST for 5 min per wash and incubated with a mix containing the secondary antibodies; A31552 (AlexaFluor350 goat anti-mouse IgM) diluted 1:500; A21121 (AlexaFluor488 goat anti-mouse IgG1) diluted 1:200; A11077 (AlexaFluor568 goat anti-rat IgG) diluted 1:500. All secondary antibodies were supplied by Molecular Probes, Invitrogen, Netherlands. The sections were left at room temperature for 1 h in a dark, humidified chamber and then subjected to a further 3 washes with PBST for 5 min each. The slides were left to air-dry in the dark for 1 h and then mounted with a coverslip using Fluormount (SigmaAldrich, UK) before being stored at 4 8C until further use.
Laser Capture. The PALM LCM system (Carl Zeiss, Bernried, Germany) with a 20 3 objective and a fluorescein isothiocyanate (FITC) filter (395-490 mm) was used to select fluorescent, type II fibers (type II). Nonfluorescing fibers (2-) were identified as type I fibers. Hybrid fibers were not separately captured or identified; the level of fluorescence to categorize fibers was determined by the operator. The 2 fiber populations were laser captured using Auto-LPC mode onto separate 0.5 ml silicone, opaque adhesive caps (Carl Zeiss, Germany). Nine cryosections per subject were pooled onto 1 collection cap, translating into the capture of 1,000 to 3,000 muscle fiber sections per subject.
Image Capture for Fiber Typing. Images were recorded with a Zeiss Axiovert 200M inverted microscope (Carl Zeiss microimaging, Jena, Germany) equipped with a Hamamatsu ORCA-ER camera (Hamamatsu Photonics K.K., Japan) under a 10 3 objective using 3 filters: 4 0 ,6-diamidino-2-phenylindole (ultraviolet, 395-410 nm), FITC (490-505 nm), and tetramethylrhodamine (540-580 nm). Images were analyzed using Volocity 6.0 software (PerkinElmer, USA).
Fiber Typing. A minimum of 100 fibers were analyzed per subject. For each individual, the numbers of type I, I/IIa, IIa, and IIx fibres were recorded to calculate proportions.
RNA Extraction. RNA was extracted using the RNAeasy FFPE kit (Qiagen, UK) according to manufacturer's instructions for laser captured samples and the Trizol method for whole muscle samples as described previously, 28 before being stored at -80 8C. Complementary DNA Synthesis. For complementary DNA (cDNA) synthesis, Superscript II enzyme (Invitrogen, UK) was used for laser captured RNA. One-half microliter of random primers and 2 ll of deoxynucleotide triphosphate (dNTP) were added to 12 ll of the RNA solution and heated to 65 8C for 5 min before being placed on ice for 2 min. Four microliters of 5 3 first strand (FS) buffer, 2 ll of 0.1 M dithiothreitol (DTT), and 1 ll Riboblock (RNAsin) were added to each sample, and the sample was incubated at 25 8C for 2 min. One-half microliter of Superscript II was then added to each sample, and the samples incubated at 42 8C for 50 min, followed by 70 8C for 15 min. The final 20 ll of cDNA was diluted with 80 ll of sterile water.
For RNA extracted from whole muscle, the Omniscript RT kit (Qiagen, UK) for whole muscle RNA. One-hundred fifty nanograms of RNA in 11 ll was heated at 65 8C for 5 min before the addition of 2 ll 10 3 RT buffer, 2 ll dNTPs 5 nM, 2 ll RNAse-free H20, 1 ll Omniscript, 1 ll dithiothreitol, 0.5 ll random primers, and 0.5 ll Riboblock RI and incubation on ice for 2 min. The solution was then incubated at 42 8C for 2 h. A total of 180 ll of RNAse free water was then added. All cDNA was stored at -20 8C.
Quantitative Polymerase Chain Reaction. The quantitative polymerase chain reaction (qPCR) analysis was carried out on all samples in duplicate per target gene using 10 ll of the SyBR Green mix (Qiagen, UK), 3 ll of sterile water, 2 ll of 1 lM forward/reverse primer mix, and 3 ll of cDNA per reaction. The reaction was set up in 96-well plates with a cover, using the 7500 Fast Real Time (Applied Biosystems, UK) and the following program: 95 8C for 1 min, then 40 cycles of 95 8C for 10 s, and 60 8C for 30 s. The integrity of PCR products was confirmed by single melt curves, and where this was not evident, by gel electrophoresis to confirm expected target size. Relative gene expression was determined by means of mean threshold cycle (C T ) values (2 -CT ), which were normalized against a geometric mean of 3 housekeeper genes: 18S, beta-2-microglobulin, and the large ribosomal protein gene RPLPO. Target primers are listed in Table 1 .
Statistical
Analyses. Two-tailed Mann-Whitney tests were used to examine between-group differences. Graphpad Prism v5.0 software was used for statistical analyses. All descriptive continuous variables are expressed as median (interquartile range). Significance was accepted as P < 0.05.
RESULTS
Baseline demographics of the chosen subjects are shown in Table 2 . The 2 groups were well matched for age and body mass index, and all were Caucasian men. As expected, subjects with COPD had lower fat free mass, quadriceps strength, and exercise tolerance. COPD subjects had a significantly lower proportion of type I fibers than healthy subjects (P 5 0.04). Immunofluorescent staining and subsequent separation and laser capture of fluorescent type II fibers (type II) is illustrated in Figure 1 .
A panel of genes was analyzed, with robust amplification of all 3 housekeeping genes (18S, beta-2-microblobulin, and RPLPO); C t in the laser captured samples occurred approximately 5 cycles later than that for whole muscle samples, which is consistent with low levels of RNA in the LCM samples.
Because we captured a variable number of fibers per subject, we adjusted the MHC II (MHC IIa and IIx) content to MHC I content to give relative MHC II in each fiber population. Because MHC IIa and IIx should be more highly expressed in type II fibers and MHC I more highly expressed in type I fibers, a ratio of relative MHC II content in type II/type I fibers should be >1. In all subjects except 1, both the relative MHC IIa ratio and MHC IIx ratio gave a value of >1 when the type II fiber population was normalized to the type I population, as shown in Figure 2a . For relative MHC IIa, the ratio ranged between 0.7 and 12.4 (median, 3.8) for COPD subjects and a range of 1.5 and 25.2 (median, 3.7) for controls. For relative MHC IIx, the range was between 1.2 and 16.5 (median, 2.5) for COPD subjects and between 2.6 and 6.8 (median, 3.8) for controls, denoting good separation. Samples from the subject who did not have a ratio of >1 for both MHC IIa and MHC IIx were excluded from further analysis.
As a further validation step, we examined troponin T (TNNT-1), which is known to be highly expressed in type I myofibers. 29, 30 In samples from both COPD and healthy subjects, TNNT-1 expression was indeed greater in the type I fibers than the type II fibers (P < 0.01). When TNNT-1 content in the type I fibers versus type II fibers is expressed as a ratio, the ratio should be above 1, which is confirmed in all the COPD and control subjects (Fig. 2b) , with a mean ratio of 5.8 (range 1.1 to 27.2).
To determine whether it was feasible to study molecular signaling of protein synthesis or degradation, we examined gene expression of insulin- like growth factor-1 (IGF-1), myostatin, MURF-1, and Atrogin-1 in whole muscle and laser captured samples because these genes are expressed in high quantities in muscle. Whole muscle sample analyses did not reveal significant differences between COPD and control subjects for any of the target genes analyzed (Fig. 3) . For laser captured samples, we analyzed expression for type II fibers, type I fibers, and type II:I ratio, the latter representing relative fiber expression. Analysis of the type I fibers did not reveal significant differences between COPD and control subjects for any of 
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Successfully captured type II material fluorescing on the adhesive silicon cap, which is then subject to RNA extraction. TNNT-1 gene expression was determined by qPCR and normalized to a geometric mean of 18S, beta-2-microglobulin, and RPLPO expression in laser captured type II and type I fibers from 11 COPD subjects and 6 healthy controls (total n 5 17). The mean TNNT-1 ratio was 5.77, which is illustrated by the horizontal bar. these target genes (Fig. 4) . There was reduced MURF-1 and Atrogin-1 expression in the type II fibers of COPD subjects as compared to controls (P 5 0.02 and P 5 0.03, respectively), but no significant difference in myostatin or IGF-1 expression (Fig. 5) . When comparing the type II:I ratio, there was a significant reduction in relative type II MURF-1 expression in the COPD subjects in comparison to the healthy subjects (P 5 0.03). No difference was observed for IGF-1, Atrogin-1, and myostatin mRNA (Fig. 6 ).
DISCUSSION
We describe a method which allows successful LCM of the 2 principal fiber types in human locomotor muscle specimens. Using this technique, we were able to show, in an exemplar feasibility analysis of E3 ligase signaling pathways, that statistically significant differences could be detected at a fiberspecific level that were not apparent in whole muscle samples, the latter having been used in prior efforts in this field. We report fiber-specific changes in MURF-1 and Atrogin-1 signaling in human skeletal muscle, using LCM to more precisely study the quadriceps of COPD patients.
Significance of the Findings. That fiber-specific signaling should exist in skeletal muscle is supported by 3 other previously published studies. Morissette et al. demonstrated fiber-specific SERCA-2 changes following exercise in murine models, 31 and Santoro et al. 19 showed that there is differential expression of the human insulin receptor gene in their comparative study of 6 patients with myotonic dystrophy and 2 control subjects. Vanderburg and Clarke demonstrated lower MURF-1 and Atrogin-1 gene expression levels in type IIB fibers, but higher Atrogin-1 levels in type I fibers of atrophied gastrocnemius muscle from rats undergoing hind limb suspension versus controls. 20 While the application of the latter model has its limitation in humans, it is interesting to note that the findings in type II fibers in human COPD muscle mirror those of Vanderburg and Clarke, which suggests that the ubiquitin-proteasome system is not as active in type II fibers in COPD and that different pathways are activated in individual fiber types mediating differential atrophy of myofibers in COPD.
In this proof of principle study, we are limited by subject numbers, but our data do permit some observations. MURF-1 and Atrogin-1 were expressed at lower levels in type II fibers of COPD subjects than in those from healthy controls, but not in type I fibers. This would tend to favor survival of type II rather than type I fibers in keeping with the known fiber shift in COPD. This finding alone does not fully explain the fiber shift in COPD or the reason for type I fiber atrophy, and impaired protein synthesis or other catabolic processes such as autophagy may play an important role. However, LCM could allow fiber-specific examination of these processes in the future to determine their contribution to muscle dysfunction in COPD.
Similarly, myostatin, a negative regulator of muscle mass, has previously been reported to be elevated in weak 32 patients with COPD, while Plant et al. showed increased MURF-1 and Atrogin-1 levels in the presence of increased myostatin. 12 Although we did not detect a significant difference in myostatin levels between COPD and healthy subjects in our whole muscle or type I fibers, myostatin expression was numerically lower in type II fibers (P 5 0.08). While this finding just failed to achieve statistical significance in this preliminary study, a higher myostatin level in type I fibers would tend to promote relative type I fiber atrophy.
Differential activation of pathways between fibers is important to consider for stratification of patients when designing future therapeutic agents. In addition, this technique provides more sensitive analyses, showing differences in gene expression in specimens enriched by fiber type where no significant differences could be detected in whole muscle. This technique, therefore, could potentially reduce the minimum sample size required and allowing identification of new targets that were previously overlooked after whole muscle analysis. Molecular studies using whole muscle from small numbers of COPD patients are at particular risk of failing to account for fiber-specific changes due to the heterogeneity in fiber type composition in COPD patients, 33 a problem that our method circumvents.
Critique of the Method. While our method for identification and subsequent laser capture of individual muscle fiber populations is novel and offers several benefits, technical aspects require discussion. First, fixing tissue in formalin allows time for immunostaining, which confers advantages over histochemical staining for fiber typing. Histochemical staining is critically dependent on pH, temperature, and duration of staining. It is also time consuming and requires serial sections to be stained at a different pH, as with SDH staining used by Picard et al. 34 or ATPase staining used by Santoro et al. 19 Our method can potentially be modified to further subcategorize fibers into IIa and IIx fibers, or to differentiate satellite cells, although these form a very small portion of each section, therefore, limiting RNA yield. Our method is also much simpler than metachromatic staining, a modified histochemical technique used by Vanderburg and Clarke requiring at least 30 changes of solutions per slide as opposed to 12 changes of solution in our protocol. 20 Our technique is potentially automatable with recognition of relevant fluorescent targets by means of computer programming. Automation would remove operator discretion for determining fluorescence and categorization of fibers, therefore, potentially improving inter-and intra-observer reliability. We only used a single observer, however, thereby limiting confounding of results. Second, formalin fixation also allows for time with laser capture without significant ongoing degradation of RNA at room temperature, which in turn allows capture of significantly more muscle tissue. For instance, Santoro et al. captured only 100 fibers per subject, and Vanderburg and Clarke captured 500 fibers per subject; both groups minimized the time that samples spent at room temperature. In contrast, we were able to capture up to 3,000 fiber sections with samples exposed to room temperature for up to 2 days, albeit with a lower RNA yield per section. We note that previous studies have set a predetermined number of fibers to be captured per subject thus making betweensubject comparisons easier; we chose instead to capture as much material as possible from 9 cryosections after finding that 3 cryosections failed to give adequate yields for MURF-1 and Atrogin-1 determination. Our use of serial sections means that the same myofiber may have been sampled across different sections. Third, frozen OCTembedded samples can be analyzed, therefore allowing retrospective analysis of existing biobanks.
Our technique uses formalin, which allows for rapid tissue penetration but results in extensive cross-linking of nucleic acids and gives low yields for RNA. Furthermore, formalin fixation can cause fragmentation of RNA; therefore, PCR analysis of cDNA requires careful primer selection to target short gene sequences. However, it has been recognized previously that it is feasible to analyze gene expression from formalin-fixed samples using LCM in tissues other than skeletal muscle. 35, 36 Additionally, robust amplification of all 3 housekeeping genes in each laser captured sample lends support to the integrity of the RNA captured.
Although immunostaining can allow individual fiber identification, separation of tissue by means of laser capture is not completely clean. There can be contamination from surrounding tissue as well as incomplete lifting of a target fiber from the slide, resulting in an enriched population of fibers, rather than a single fiber type. In this regard, we caution that it is more appropriate to regard this technique as a method for enriching specimens by fiber type rather than achieving a complete separation.
Further development of the technique could explore the use of fixatives such as dithiobis (succinimidyl) propionate, a reversible cross-linker, for greater RNA yield than with formalin fixation. 37 Additionally, ethanol-fixed tissue could be used to examine fiber-specific protein expression, which we were unable to perform in our samples. We only examined gene expression, which does not faithfully represent activity of a particular pathway, e.g., the E3 ligase system. Using LCM to combine examination of gene expression and proetomics will, therefore, be important in the future to fully assess single muscle fiber physiology.
Compared with studies which have examined whole muscle specimens, this study may be considered relatively small, although it is the largest study to date that examines fiber-specific gene expression in human muscle. Moreover, because we confined our population to men, the data regarding signaling pathways cannot be uncritically generalized to women with COPD. Additionally, our small sample size may mean that this study is underpowered to detect differences in type I fibers between COPD and control subjects. We only examined quadriceps biopsies; therefore, it is feasible that the pattern of changes in gene expression discussed here are different in other muscle groups. Indeed, given that the distribution of peripheral muscle dysfunction in COPD is regional, it is likely that similar changes would not have been observed in the deltoid muscle. An opposite pattern might have been observed in the diaphragm, where there is an increase in type I fiber proportion in COPD. However, our technique could address differences in gene expression between muscle groups, but the primary aim of this study was to develop the methodology and to show in principle that this method could identify differences which were not apparent from analysis of whole muscles.
Finally, an outlier in the control group appears to skew the data to result in statistically significant differences between COPD and healthy subjects for MURF-1 and Atrogin-1 in terms of the type II fiber population. Even with the outlier removed, the same level of significance is retained for differences in the type II population for MURF-1 (P < 0.05), and Atrogin-1, approaching significance (P 5 0.06) and suggesting that the observed differences are not simply explained by the outlier.
In summary, we report fiber-specific MURF-1 and Atrogin-1 signaling in human skeletal muscle, which could have important implications for development of future anabolic agents in COPD, as well as other conditions where there is peripheral muscle atrophy, such as chronic heart failure. Although the technique, when undertaken manually, remains labor intensive compared with analysis of whole muscle we suggest the use of LCM be considered part of the portfolio of techniques available for analysis of future molecular signaling in human muscle, given that analysis of whole muscle samples may not fully accommodate the heterogeneity in fiber type composition between COPD subjects.
